This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01148459
First received: June 17, 2010
Last updated: April 6, 2017
Last verified: April 2017
June 17, 2010
April 6, 2017
July 30, 2010
May 24, 2013   (Final data collection date for primary outcome measure)
Number of subjects with serious adverse events (SAEs) [ Time Frame: During the entire study period (from 30 days before Dose 1 up to Month 14) ]
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Occurrence of SAEs [ Time Frame: From the time of first vaccination until 14 months post Dose 1 ]
Complete list of historical versions of study NCT01148459 on ClinicalTrials.gov Archive Site
  • Number of subjects with any and Grade 3 solicited local symptoms [ Time Frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses ]
    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.
  • Number of subjects with any, Grade 3 and related solicited general symptoms [ Time Frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses ]
    Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability/fussiness = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination.
  • Number of subjects with any unsolicited adverse events (AEs) [ Time Frame: During the 30-day (Days 0-29) post-vaccination period ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
  • Number of subjects with non-malaria related SAEs [ Time Frame: During the entire study period (from 30 days before vaccine Dose 1 up to Month 14) ]
    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Anti-CS antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ]
  • Anti-HBs antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ]
  • Anti-CS antibody titers [ Time Frame: 12 months post Dose 3 ]
  • Anti-HBs antibody titers [ Time Frame: 12 months post Dose 3 ]
  • Occurrence of malaria disease according to specific case definitions [ Time Frame: From Day 0 to Day 420 ]
  • Asexual P. falciparum parasitemia prevalence and density [ Time Frame: 12 months post Dose 3 ]
  • HIV viral load [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ]
  • Rate of positive CD4 and absolute cell counts [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ]
  • WHO HIV clinical classification progression [ Time Frame: At baseline, one month, 6 months and 12 months post Dose3 ]
  • Growth parameters: weight, age/length and middle upper arm circumference for age score [ Time Frame: At Day 0 and Day 420 ]
  • Occurrence of solicited general and local reactions [ Time Frame: After each vaccine administration over a 7 day follow-up period (day of vaccination and 6 subsequent days) ]
  • Occurrence of unsolicited symptoms [ Time Frame: After each vaccine administration over a 30 day follow-up period (day of vaccination and 29 subsequent days) ]
  • Occurrence of non-malaria related SAEs [ Time Frame: From the time of first vaccination until 14 months post Dose 1 ]
  • Anti-CS antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ]
  • Anti-HBs antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ]
  • Anti-CS antibody titers [ Time Frame: 12 months post Dose 3 ]
  • Anti-HBs antibody titers [ Time Frame: 12 months post Dose 3 ]
  • Occurrence of malaria disease according to specific case definitions [ Time Frame: From Day 0 to Day 420 ]
  • Asexual P. falciparum parasitemia prevalence and density [ Time Frame: 12 months post Dose 3 ]
  • HIV viral load [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ]
  • Rate of positive CD4 and absolute cell counts [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ]
  • WHO HIV clinical classification progression [ Time Frame: At baseline, one month, 6 months and 12 months post Dose3 ]
  • Growth parameters: weight, age/length and middle upper arm circumference for age score [ Time Frame: At Day 0 and 420 ]
Not Provided
Not Provided
 
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children
The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children
This protocol posting has been updated due to protocol Amendment 2.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Malaria
  • Biological: GSK Biological's Investigational Malaria Vaccine 257049
    All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
  • Biological: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);

    To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.

    The vaccine will be administered intramuscularly

  • Biological: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).

    To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.

    The vaccine will be administered intramuscularly.

  • Experimental: Group A
    Infants enrolled to this group will receive 3 doses of the experimental vaccine.
    Intervention: Biological: GSK Biological's Investigational Malaria Vaccine 257049
  • Active Comparator: Group B
    Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
    Interventions:
    • Biological: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);
    • Biological: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
Otieno L, Oneko M, Otieno W, Abuodha J, Owino E, Odero C, Mendoza YG, Andagalu B, Awino N, Ivinson K, Heerwegh D, Otsyula N, Oziemkowska M, Usuf EA, Otieno A, Otieno K, Leboulleux D, Leach A, Oyieko J, Slutsker L, Lievens M, Cowden J, Lapierre D, Kariuki S, Ogutu B, Vekemans J, Hamel MJ. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2016 Oct;16(10):1134-44. doi: 10.1016/S1473-3099(16)30161-X. Epub 2016 Jul 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 24, 2013
May 24, 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

  • A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first vaccination.
  • Signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the infant or child. Where parents/LARs are illiterate, the consent form will be countersigned by a witness.
  • Subjects who the investigator believes that their parents/LARs can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects who are known to be HIV-infected (documented positive DNA PCR), whether taking HIV antiretroviral treatment (ART) or not.
  • Subjects who are born following a normal gestation period.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

  • Acute disease at the time of enrolment. However, the presence of an illness listed as Grade I or Grade II (WHO pediatric AIDS clinical staging) will not of itself constitute an exclusion criterion. Enrolment should be deferred if axillary temperature is >=37.5°C.
  • Grade III or Grade IV abnormality on screening laboratory blood sample.
  • Grade III or IV AIDS at the time of enrolment (WHO pediatric AIDS clinical staging).
  • Major congenital defects.
  • Planned administration/administration of a vaccine not foreseen by the study protocol prior to or within 7 days of study vaccine.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine 30 days preceding Dose°1 of study vaccine, or planned use during the study period.
  • Previous participation in any other malaria vaccine trial.
  • Simultaneous participation in another clinical trial including administration of experimental treatment.
  • Same sex twins.
  • History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.
  • History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.
  • Child in care.
Sexes Eligible for Study: All
6 Weeks to 17 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Kenya
 
 
NCT01148459
112745
Not Provided
Not Provided
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP